Page 224 - Read Online

Tang et al. Hepatoma Res 2019;5:19 I http://dx.doi.org/10.20517/2394-5079.2019.07 Page 9 of 9

27. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, et al. Overall survival and long-term safety of nivolumab (Anti-programmed
death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol
2015;33:2004-12.
28. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, et al. Nivolumab versus chemotherapy in patients with advanced melanoma
who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol
2015;16:375-84.
29. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N
Engl J Med 2013;369:134-44.
30. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic
bladder cancer. Nature. 2014;515:558-62.
31. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s
lymphoma. N Engl J Med 2015;372:311-9.
32. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, et al. Disabling immune tolerance by programmed death-1 blockade with
pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international
phase II trial. J Clin Oncol 2013;31:4199-206.
33. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin
Oncol 2012;30:2691-7.
34. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol
2013;94:41-53.